Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: A Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2654-2660

  Oechsle, K ^a   Honecker, F ^a   Cheng, T ^b   Mayer, F ^c   Czaykowski, P ^d   Winquist, E ^e   Wood, L ^f   Fenner, M ^g   Glaesener, S ^a   Hartmann, J T ^c   Chi, K ^h   Bokemeyer, C ^a   Kollmannsberger, C ^h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TOM BAKER CANCER CENTRE   (Canada)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF MANITOBA   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Angiogenesis; Cisplatin resistance; Germ cell tumor; Relapse; Sunitinib

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LACTATE DEHYDROGENASE; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE; SUNITINIB; TETRAZOLIUM; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ANOREXIA; ARTICLE; BONE METASTASIS; CANADA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; DIARRHEA; DISEASE DURATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DYSPEPSIA; FATIGUE; FEASIBILITY STUDY; GERM CELL TUMOR; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEMINOMA; TESTIS CANCER; TUMOR LOCALIZATION; VISCERAL METASTASIS;

EID: 79960860865     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr026     Document Type: Article

References (38)

1. Porcu P, Bhatia S, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 2000; 18: 1181-1186.
2. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 17: 36-39.
3. Motzer RJ, Bajorin D, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-2283.
4. Bokemeyer C, Gerl A, Schöffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999; 17: 512-516.
5. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999; 17: 509-511.
6. Kollmannsberger C, Rick O, Derigs H-G et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20: 2031-2037.
7. Hinton S, Catalano PJ, Einhorn L et al. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol 2001; 20: 1859-1863.
8. Bokemeyer C, Oechsle K, Honecker F et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008; 19: 448-453.
9. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22: 108-114.
10. Oechsle K, Kollmannsberger C, Honecker F et al. Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin ± paclitaxel. J Clin Oncol 2010; 28: 15s (Abstr 4585).
11. Honecker F, Wermann H, Mayer F et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009; 27: 2129-2136.
12. Viglietto G, Romano A, Maglione D et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996; 13: 577-587.
13. Bentas W, Beecken W, Glienke W et al. Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors. Urol Res 2003; 30: 390-393.
14. Fukuda S, Shirahama T, Imazono Y et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999; 85: 1323-1330.
15. Adam M, Schmidt D, Wardelmann E et al. Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol 2003; 44: 329-336.
16. Abraham D, Abri S, Hofmann M et al. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J Urol 2003; 170: 1388-1393.
17. Castillo-Avila W, Piulats JM, Garcia Del Muro X et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res 2009; 15: 3384-3395.
18. Andrews PW. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol 1984; 103: 285-293.
19. Teshima S, Shimosato Y, Hirohashi S et al. Four new human germ cell tumor cell lines. Lab Invest 1988; 59: 328-336.
20. Glaesener S, Honecker F, Veltman IM et al. Comparative proteome, transcriptome, and genome analysis of a gonadal and an extragonadal germ cell tumor cell line. J Proteome Res 2008; 7: 3890-3899.
21. Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-939.
22. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-2645.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
25. Pectasides D, Pectasides M, Farmakis D et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004; 15: 493-497.
26. Fenner MH, Beutel G, Grunwald V. Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs 2008; 17: 511-522.
27. Kollmannsberger C, Honecker F, Bokemeyer C. Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother 2008; 9: 2259-2272.
28. Muller-Tidow C, Schwable J, Steffen B et al. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 2004; 10: 1241-1249.
29. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
30. Potapova O, Laird AD, Nannini MA et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006; 5: 1280-1289.
31. Hui EP, Lui VW, Wong CS et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs 2010. [Epub ahead of print].
32. Kemmer K, Corless CL, Fletcher JA et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164: 305-313.
33. Coffey J, Linger R, Pugh J et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 2008; 47: 34-42.
34. Feldman DR, Turkula S, Ginsberg MS et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs 2009; 28: 523-528.
35. Suddek GM. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals. Cancer Chemother Pharmacol 2010. [Epub ahead of print].
36. Ramasubbaiah R, Brames J, Johnston EL et al. Phase II study of oxaliplatin (O) and bevacizumab (B) chemotherapy in refractory germ cell tumors (GCT). J Clin Oncol 2010; 28: (Abstr e15054).
37. Galsky MD, Sonpavde G, Hellerstedt BA et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). J Clin Oncol 2010; 28: 15s (Abstr 4573).
38. Reck M, Frickhofen N, Cedres S et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose escalation study. Lung Cancer 2010; 70: 180-187.